Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

Detalles Bibliográficos
Autores principales: Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., Davis, M.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723677/
https://www.ncbi.nlm.nih.gov/pubmed/19609501
http://dx.doi.org/10.1007/s00125-009-1452-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723677/
https://www.ncbi.nlm.nih.gov/pubmed/19609501
http://dx.doi.org/10.1007/s00125-009-1452-2

Ejemplares similares